Congresses

Title Yearsort ascending
OPTIKA, A New High Content Drug Combination Kill Kinetic Assay 2022
Implementing best practises on data generation and reporting of Mycobacterium tuberculosis time kill assays: a case study of standardized protocol within the ERA4TB consortium 2022
Shortening Buruli Ulcer treatment: the BLMS4BU clinical trial 2022
Strategies to elucidate the mode of action of the avermectins against mycobacteria 2021
Beta-lactams against Mycobacterium kansasii 2021
Novel in vitro synergistic combinations in the treatment of non-tuberculous mycobacteria 2021
Enzymatic inhibition of Mycobacterium tuberculosis DprE1 protein by the anti-parasitic selamectin lacks translation into phenotypic activity 2021
Approaches to elucidate the mode of action of a novel chemical series active against mycobacteria 2021
Clinical trial design optimisation and dose rationale for the treatment of Buruli ulcer antibiotic combination therapy 2021
Repurposing beta-lactams for Buruli ulcer therapy, from the bench to the clinic. 2021
IMPLEMENTATION OF THE HOLLOW FIBER SYSTEM FOR ANTIMICROBIAL RESEARCH 2020
Resistance to selamectin in Mycobacterium smegmatis is associated with changes in the mycobacterial envelope 2020
Expert Campus | Focus on tuberculosis 2020
Fighting Mycobacterium abscessus infection in Cystic Fibrosis patients 2020
Expert campus | Focus on tuberculosis 2020
Repurposing beta-lactams for Buruli ulcer therapy 2020
Discovering the mode of action of a novel chemical series active against mycobacteria and other microbial pathogens 2020
Repurposing beta-lactams for Buruli ulcer therapy 2020
Repurposing avermectins for the treatment of infections by non-tuberculous mycobacteria 2020
Development Of An Efficient In Vitro High-Throughput Method To Discover New Combinatorial Therapies Against Non-Tuberculous Mycobacteria 2020

Pages